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Imported 
Ciproﬂ  oxacin-
Resistant Neisseria 
meningitidis 
To the Editor: Emergence and 
spread of antimicrobial drug resistance 
in community-acquired infections is a 
global threat. Resistance of Neisseria 
meningitidis raises concern because 
of severity of disease caused by this 
organism and the need for immediate 
treatment of infected patients.
We report an imported case of 
meningococcal disease caused by ﬂ  u-
oroquinolone-resistant  N. meningiti-
dis. The patient, a previously healthy, 
unvaccinated 43-year-old man who 
had traveled internationally, was hos-
pitalized because of high fever, neck 
stiffness, and a diffuse petechial rash 
Signs and symptoms were observed 
24 hours after he had returned to It-
aly from a 10-day business trip dur-
ing February–March 2009, to New 
Delhi and Chennai in India and a 
stopover of a few hours in Frankfurt, 
Germany.
Microscopic examination of cere-
brospinal ﬂ  uid showed gram-negative 
diplococci and culture documented N. 
meningitidis serogroup A. The strain 
was characterized as serotype 4,21 
subtype P1.9 by using monoclonal an-
tibodies. Multilocus sequence typing 
performed at the National Reference 
Laboratory for Invasive Meningococ-
cal Diseases in Rome characterized 
the strain as sequence type (ST)-4789 
and belonging to clonal complex ST-5/
subgroup III.
Antimicrobial drug susceptibility 
was determined by using an agar dilu-
tion test, and MICs were determined by 
using an agar disk-diffusion test (Etest; 
AB Biodisk, Solna, Sweden) and stan-
dard techniques. The strain was re-
sistant to ciproﬂ  oxacin, levoﬂ  oxacin, 
and trimethoprim/sulfamethoxazole 
and susceptible to penicillin, ampi-
cillin, ceftriaxone, chloramphenicol, 
rifampin, and azithromycin. MICs for 
ciproﬂ  oxacin, levoﬂ  oxacin, penicillin, 
ampicillin, and ceftriaxone were 0.25, 
0.25, 0.03, 0.12, and <0.016 mg/L, re-
spectively (Figure). The patient recov-
ered after treatment with ceftriaxone.
Before results of antimicrobial 
drug–susceptibility testing were avail-
able, 15 adult contacts of the patient 
received ciproﬂ   oxacin as chemopro-
phylaxis according to public health 
recommendations in Italy. After posi-
tive test results, all contacts were of-
fered repeat chemoprophylaxis with 
rifampin; 13 of them accepted. A di-
agnosis of meningitis and results of 
antibiograms were sent to the patient’s 
place of employment in India and 
to the airport manager in Frankfurt. 
However, we were not able to assess 
what chemoprophylaxis was given to 
the patient’s fellow employees and air 
travel contacts. No secondary cases 
have been detected so far in Italy.
Sporadic cases of infection with 
N. meningitidis (mainly serogroup B) 
with reduced susceptibility to cipro-
ﬂ  oxacin have been reported in Europe, 
North and South America, and Austra-
lia since 2000 (1–4). Ciproﬂ  oxacin-re-
sistant N. meningitidis of serogroup A 
caused an outbreak of meningococcal 
meningitis in Delhi, India, in 2005 and 
a recurrence in 2006 (5). Although the 
patient reported in our study had no 
known contact in India with patients 
who had meningococcal disease, mul-
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tilocus sequencing typing analysis 
showed that the isolate had the same 
sequence type as isolates from the epi-
demic in India (5,6). 
We report isolation of an im-
ported, ciproﬂ  oxacin-resistant  strain 
of  N.  meningitidis isolated from a 
patient with meningococcal disease. 
During the past 2 years, 182 strains 
of N. meningitidis have been sent to 
the Istituto Superiore di Sanità; all 
were susceptible to ciproﬂ  oxacin 
and MICs ranged from 0.002 mg/L 
to 0.006 mg/L (National Reference 
Laboratory for Invasive Meningococ-
cal Diseases, pers. comm.) Serogroup 
A N. meningitidis accounted for only 
1 of these strains; serogroups B and 
C are the most common groups in 
Italy. In contrast, group A meningo-
cocci are the major cause of menin-
gitis outbreaks worldwide, especially 
in Africa and Asia. To date, spread of 
ciproﬂ  oxacin resistance in serogroup 
A appears to be limited to India be-
cause a recent report of antimicrobial 
drug susceptibility of N. meningitidis 
in the meningitis belt of Africa dur-
ing 2000–2006 showed no evidence 
of ciproﬂ  oxacin resistance (7).
Temporal correlation and epide-
miologic features strongly suggest that 
transmission of N. meningitidis to our 
patient occurred during his journey to 
India. Meningococcal disease is rarely 
imported because onset of symptoms 
is often rapid and severe. Nonetheless, 
the enormous increase in global trade 
and travel and shortening of interna-
tional travel time may increase the 
risk for spread of infectious diseases 
and drug-resistant organisms. In addi-
tion, carriage of N. meningitidis in the 
nasopharynx of otherwise healthy per-
sons can occur.
Emergence of ﬂ  uoroquinolone re-
sistance in some countries raises con-
cerns about current chemoprophylaxis 
recommendations for meningococcal 
disease. Ciproﬂ  oxacin is widely used 
for postexposure prophylaxis of close 
contacts of infected persons because 
it is simple to use (single oral dose) 
and lacks toxicity. However, patients 
and their contacts should be ques-
tioned about possible recent travel. 
When transmission of N. meningitidis 
is suspected in regions where ﬂ  uoro-
quinolone resistance has been found 
(New Delhi, India, and North Dakota 
and western Minnesota in the United 
States), alternative chemoprophy-
laxis such as rifampin or ceftriaxone 
should be used.
Emergence of autochthonous cipro-
ﬂ  oxacin-resistant  N.  meningitidis is 
possible in countries where ﬂ  uoroqui-
nolones are widely used. In vitro drug 
susceptibility testing is not routinely 
and uniformly used in all settings be-
cause treatment or chemoprophylaxis 
are usually started before antibiogram 
results are available. Our case demon-
strates that drug susceptibility testing 
should be encouraged and routinely 
performed for all isolates. Local and 
worldwide surveillance for antimicro-
bial drug–resistant N.  meningitidis is 
crucial for determining antimicrobial 
drug resistance trends and future rec-
ommendations for chemoprophylaxis 
and treatment.
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Figure. Antimicrobial drug–susceptibility test, showing resistance to levoﬂ  oxacin  (LEV, 
lower strip), ciproﬂ  oxacin (CIP, upper strip), and nalidixic acid (NA, disk) for the strain of 
Neisseria meningitidis isolated from the patient. A color version of this ﬁ  gure is available 
online (www.cdc.gov/EID/content/15/11/1852-F.htm).LETTERS
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Imported 
Chikungunya Virus 
Strains, Taiwan, 
2006–2009 
To the Editor: Chikungunya is a 
reemerging infectious disease that is 
endemic to Africa and Asia and caused 
by a mosquito-borne alphavirus in the 
family Togaviridae. Previous phyloge-
netic studies showed that chikungunya 
virus (CHIKV) strains were clustered 
into 3 distinct genotypes separated pri-
marily by location into West African, 
Central/East/South African, and Asian 
genotypes (1,2).
Earlier outbreaks in Thailand, 
Cambodia, Vietnam, Myanmar, the 
Philippines, Malaysia, Indonesia, 
Pakistan, and India during 1960–1999 
were caused by strains of the Asian 
genotype (2). However, explosive 
epidemics in Indian Ocean islands 
and India since 2005 and the world-
wide increase in travel have changed 
the distribution of CHIKV genotypes. 
Recent studies have shown that differ-
ent lineages of CHIKV strains of the 
Central/East/South African genotype 
have expanded locally and spread to 
new areas in Africa, Europe, and Asia 
and caused epidemics (2–7).
Imported chikungunya cases were 
identiﬁ  ed at airports by active surveil-
lance (fever screening) in Taiwan (3). 
Among 14,289 febrile patients arriv-
ing at Taiwan Taoyuan International 
Airport from January 2006 through 
February 2009, a total of 13 were 
conﬁ  rmed to have CHIKV infections. 
One additional chikungunya case was 
detected at Kaohsiung International 
Airport among 801 febrile patients 
from February 2008 through Febru-
ary 2009. These imported cases were 
introduced from Indonesia (7 cases), 
Malaysia (4 cases), Singapore (1 
case), Bangladesh (1 case), and India 
(1 case). Real-time quantitative re-
verse transcription–PCR showed virus 
titers ranged from 103.6 PFU/mL to 
106.4 PFU/mL for day 1–3 acute-phase 
serum samples from these patients. 
CHIKV strains were successfully iso-
lated by using a cell culture (C6/36) 
method (online Technical Appendix, 
available from www.cdc.gov/EID/
content/15/11/1854-Techapp.pdf).
To identify genetic relationships 
among these 14 imported CHIKV 
isolates, complete structural poly-
protein gene sequences of 10 isolates 
(GenBank accession nos. FJ807886–
FJ807895) and full genome sequences 
of 4 isolates (Singapore/0611aTw, 
Indonesia/0706aTw, Bangladesh/08
10aTw, and Malaysia/0810bTw strains) 
(GenBank accession nos. FJ807896–
FJ807899) were determined. Nucle-
otide sequences of complete open 
reading frames of Singapore/0611aTw, 
Bangladesh/0810aTw, and Malaysia/
0810bTw isolates were most closely 
related to the India IND-06-AP3 strain 
(99.95%, 99.84%, and 99.77% identi-
ties, respectively) and other India 2006 
isolates, which suggests common ge-
netic origins from India.
In comparison with other CHIKV 
strains, unique substitution K252Q 
in the envelope 2 (E2) protein was 
found in all 4 imported isolates from 
Malaysia, and 2 unique substitutions, 
V4A and N349D, in the envelope 1 
(E1) protein were found in the im-
ported Bangladesh/0810aTw isolate. 
The Indonesia/0706aTw isolate was 
most closely related to the Malaysia 
MY003IMR isolate (99.42% identi-
ty). A novel 4-aa deletion, correspond-
ing to nonstructural protein 3 codons 
379–382 (TTACCAACCATA coding 
for Leu-Pro-Thr-Ile in the Malaysia 
MY003IMR strain), was observed in 
the Indonesia/0706aTw strain when 
it was compared with other CHIKV 
sequences available in GenBank. Fur-
ther sequence analysis showed that all 
6 isolates from Indonesia had the same 
deletion in this region.
A phylogenetic tree based on 49 
CHIKV partial E1 gene sequences 
was constructed to trace the origins 
of the 14 CHIKV strains reported 
in this study (Figure). Phylogenetic 
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words 
and 10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.